Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share buyback executed on 3 June 2026, reducing its outstanding H-share count and increasing treasury holdings.

The company repurchased 53,100 H-shares on the Hong Kong Stock Exchange at prices ranging between HKD 26.00 and HKD 27.66 per share, with a volume-weighted average of HKD 27.03. The transaction totalled HKD 1.44 million.

Following the buyback: • Issued shares (excluding treasury shares) declined to 135.24 million from 135.29 million, a 0.039% reduction. • Treasury shares rose to 978,000 from 924,900. • Total issued shares (including treasury stock) remained unchanged at 136.22 million.

The purchase was made under the repurchase mandate approved on 12 February 2026, which authorises up to 13.62 million shares for buyback. Cumulative repurchases under this mandate now stand at 978,000 shares, equivalent to 0.72% of the company’s issued share capital at the mandate date.

In accordance with Hong Kong listing regulations, HANXBIO-B is subject to a 30-day moratorium on issuing new shares or transferring treasury shares, effective until 3 July 2026.